Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

NCT01910441 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Vildagliptin
DRUG: Glimepiride
DRUG: Metformin

Sponsor

Novartis Pharmaceuticals